Antigen test is Labcorp’s latest product to fight COVID-19 at every stage from diagnostic tests to clinical trials and vaccination services
Burlington, North Carolina-(BUSINESS WIRE)-Labcorp (NYSE:LH), the world’s leading life science company, today announced the launch of a laboratory-based neoantigen test that will help doctors determine if an individual is infected COVID -19.
The antigen test developed by DiaSorin can be provided to patients on a doctor’s order and can be tested to determine whether an individual is still infected with COVID-19 and may spread. The test is performed by a doctor or other medical service provider using a nasal or nasopharyngeal swab to collect the sample, which is then picked up and processed by Labcorp. The results can be obtained within 24-48 hours on average after pickup.
Dr. Brian Caveney, Chief Medical Officer and President of Labcorp Diagnostics, said: “This new highly sensitive antigen test is another example of Labcorp’s commitment to providing people with the information they need to make important health decisions.” PCR testing is still considered to diagnose COVID -19 gold standard, because they can detect the smallest trace of virus. However, antigen testing is another tool that can help people understand whether they can still carry the virus or whether they can safely resume work and life activities. ”
According to the Centers for Disease Control and Prevention (CDC), antigen testing can be used in a variety of testing strategies to respond to the COVID-19 pandemic and help determine whether a person diagnosed with COVID-19 is still infectious.
Labcorp continues to advise individuals to follow health guidelines, including wearing masks in public places, keeping distance from society, washing hands frequently and avoiding large groups of people, and receiving the COVID-19 vaccine as availability increases and CDC guidelines expand to more qualified people. For more information about Labcorp’s COVID-19 response and testing options, please visit Labcorp’s COVID-19 microsite.
The DiaSorin LIAISON® SARS-CoV-2 Ag antigen test has been provided to the U.S. market after notifying the U.S. Food and Drug Administration (FDA) in accordance with the FDA’s 2019 Coronavirus Disease Diagnostic Test Policy on October 26, 2020. Released during the “Public Health Emergency” (Revised Edition) released on May 11, 2020.
Labcorp is a leading global life science company that provides important information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostic and drug development capabilities, we can provide insights and accelerate innovation to improve health and improve lives. We have more than 75,000 employees and provide services to customers in more than 100 countries. Labcorp (NYSE: LH) reports that revenue for fiscal year 2020 will be $14 billion. Learn about Labcorp on www.Labcorp.com, or follow us on LinkedIn and Twitter @Labcorp.
This press release contains forward-looking statements, including but not limited to clinical laboratory testing, the potential benefits of the COVID-19 test home collection kit, and our opportunities for the COVID-19 pandemic and future growth. Each forward-looking statement may change due to various important factors, many of which are beyond the company’s control, including but not limited to whether our response to the COVID-19 pandemic will prove effective, and the impact of COVID-19 In our business and financial conditions as well as the general economic, business and market conditions, competitive behavior and other unforeseen changes and overall uncertainty in the market, changes in government regulations (including health care reforms, customer purchase decisions, including food And drug changes) in the pandemic payer regulations or policies, other unfavorable behaviors of the government and third-party payers, company’s compliance with regulations and other requirements, patient safety issues, testing guidelines or proposed changes, federal, state, and local The government’s response to the COVID-19 pandemic resulted in unfavorable results in major litigation matters and was unable to maintain or develop customer relationships shi ps: We have the ability to develop or acquire new products and adapt to technological changes, information technology, system or data security failures, and The ability of employee relations. These factors have been affected in some cases, and in the future (along with other factors) may affect the company’s ability to implement the company’s business strategy, and actual results may differ materially from those suggested in these forward-looking statements. Therefore, readers are cautioned not to rely too much on any of our forward-looking statements. Even if its expectations change, the company has no obligation to provide any updates to these forward-looking statements. All such forward-looking statements are all expressly bound by this warning statement. Annual report on the company’s latest Form 10-K and subsequent Form 10-Q (including under the heading “Risk Factors” in each case) and “Other documents submitted by the company to the SEC.
Post time: Feb-19-2021